MiRNA markers in septic shock patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates early microRNA changes and their association with HLA-DR expression on circulating monocytes in patients with septic shock. The aim is to improve understanding of sepsis-induced immunosuppression and its link to secondary infections and mortality. Data are collected from adults meeting Sepsis-3 criteria and requiring vasopressors, with samples taken early after septic shock onset. The study is conducted at Inselspital in Bern, led by Insel Gruppe AG/University Hospital Bern, and does not specify an intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Septic shock:

* New onset (\<24h) of septic shock diagnosis according to Sepsis-3 definition
* (suspected) infection
* Vasopressors required to maintain mean arterial pressure ≥65mm Hg (despite adequate fluid resuscitation)
* Serum lactate level \> 2mmol/L
* Minimum age of 18 years
* Expected length of stay \>48h
* Written consent from an independent physician

Critically ill:

* Patients on mechanical ventilation (MV) in the ICU without an admission diagnosis of sepsis/septic shock according to Sepsis-3 definition
* Minimum age of 18 years
* Expected length of stay \>48h
* Written consent from an independent physician

Exclusion Criteria:

* Age \< 18 years
* Patients known not to speak German or French
* Patients with known.

  1. Pre-existing congenital or acquired severe immune deficiency (e.g. severe combined immunodeficiency, HIV infection, AIDS) or
  2. current immunosuppressive therapy (immunosuppressive biologicals or active lymphocyte therapy e.g. endoxan, rituximab or corticosteroid use at a dose \> 10 mg/day equivalent of prednisone. However, acute corticosteroid treatment of a relative adrenal insufficiency using a maximum hydrocortisone dose of 200 mg/day is accepted.

Where it's running

• Inselspital
  Bern, Switzerland Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dynamic SvO2 to predict fluid responsiveness in septic shock

  This study tests whether dynamic central venous oxygen saturation can predict which septic shock patients will respond to fluid boluses.

  Recruiting Menoufia University · Menouf · NCT07516236

• Adjunctive Fludrocortisone in Septic Shock

  This study tests adding fludrocortisone to usual care for adults with septic shock to see if it helps patients survive and recover better.

  Recruiting Phase 2 Chinese University of Hong Kong · Hong Kong and 4 other locations · NCT07451886

• Ceftazidime (±avibactam) with IV fosfomycin versus ceftazidime alone for hospitalized adults with severe suspected Gram‑negative infection

  This trial will test whether adding intravenous fosfomycin to ceftazidime (or ceftazidime‑avibactam) helps hospitalized adults with suspected severe Gram‑negative infections recover faster than ceftazidime alone.

  Recruiting Phase 3 University of Geneva, Switzerland · Geneva, Canton of Geneva · NCT07063095

• Education on Immunosuppressive Therapy Reduction in Kidney Transplant Recipients in ICU with Sepsis or Respiratory Failure

  In kidney transplant patients who are in the ICU for septic shock or severe respiratory failure, the study will test a targeted approach to adjust immunosuppressive therapy and provide education to support safer care.

  Recruiting Phase 4 University Hospital, Strasbourg, France · Strasbourg · NCT06881927

• Investigating how transposable elements affect immune aging in sepsis patients

  This study looks at how certain genetic elements might affect the immune system and health outcomes in people with sepsis in the ICU.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06809868

• Assessing blood clotting issues in patients with sepsis and trauma

  This study is testing a new way to identify patients with sepsis or trauma who are at risk for dangerous blood clots and see if new blood-thinning medications can help improve their treatment.

  Recruiting at 4 sites South West Sydney Local Health District · Canberra, Australian Capital Territory and 3 other locations · NCT06680180

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.